Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765048 | 0.76 | SMN1; SMN2 (0.46) | MEN1KMT2AMAPTFAAHGAA | |
| SCHEMBL5476977 | 0.76 | GABRP (0.39) | MEN1KMT2AFAAHGAAALDH1A1 | |
| SCHEMBL4019490 | 0.73 | MAPT (0.42) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL661305 | 0.71 | MEN1 (0.55) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL5479018 | 0.70 | GABRP (0.51) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL4380345 | 0.69 | MEN1 (0.52) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL5558141 | 0.69 | MEN1 (0.62) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL5558757 | 0.67 | MEN1 (0.52) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL5528619 | 0.67 | MEN1 (0.73) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL6524461 | 0.65 | KMT2A (0.74) | MEN1KMT2AMAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | MEN1 4130/4885KMT2A 2433/4885MAPT 4013/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | MEN1 4130/4885KMT2A 2433/4885MAPT 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.